five

Dataset from A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer

收藏
NIAID Data Ecosystem2026-05-02 收录
下载链接:
https://doi.org/10.25934/PR00007706
下载链接
链接失效反馈
官方服务:
资源简介:
This will be a Phase II, open label study to establish the effect of once-daily oral doses of ZD6474 100mg in subjects with locally advanced or metastatic hereditary medullary thyroid cancer in whom no standard therapeutic option is available.
创建时间:
2024-11-26
二维码
社区交流群
二维码
科研交流群
商业服务